Vertex, NICE, NHS miss Orkambi deadline

Although NHS England, NICE and Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) have complied with a Parliament committee's request and submitted documents regarding pricing negotiations over the biotech's cystic fibrosis drugs, there is still no reimbursement deal for Orkambi lumacaftor/ivacaftor in sight, according to a statement from David Ramsden, chief executive of the U.K.-based non-profit Cystic Fibrosis Trust.

This month, the House of Commons Health and Social Care Committee said it would release the requested information on Nov. 30, if the three parties failed to reach a reimbursement deal by the end of the month. The committee did not respond in time for publication (see "U.K. Parliament Issues Ultimatum to Vertex, NHS, NICE")...